Figure 1From: Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in JapanWaterfall plot showing tumor response to axitinib by RECIST. Bars represent individual evaluable patients. Gray, partial response; black, stable disease.Back to article page